BioCryst Pharmaceuticals, Inc.: shareholders and insiders

BCRXNASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$7.32

November 19, 2026Market cap $1.8B

What Ploutos Investor adds for BioCryst Pharmaceuticals

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from 2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.

Insiders and their shares

Purchases and sales by officers and directors from Nov 19, 2025 to Sep 2, 2026, from their own Form 4 filings.

19 Form 4s

Bought on the market

–

nobody

Sold on the market

$4.1M

3 people

From Nov 19, 2025 to Nov 19, 2026, the days the chart shows. Change its range and the figures follow.

How the sales were made, as a share of their value

  • Under a set plan85%
  • The rest15%

By year

Insiders' open-market purchases (up) and sales (down), by value, since Nov 19, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.

2026·no buys·sold $2.6M by 3 people

  • 2025: no buys, sold $1.5M by 1 person
  • 2026: no buys, sold $2.6M by 3 people
  • Aug 31, 2026Jon P StonehouseDirector
    Kind
  • Aug 31, 2026Jill C. MilneDirector
    Kind
  • Aug 31, 2026Vincent MilanoDirector
    Kind
  • Aug 31, 2026Amy E McKeeDirector
    Kind
  • Aug 31, 2026Steven FrankDirector
    Kind
  • Jun 11, 2026Jill C. MilneDirector
    Kind
  • Jun 11, 2026Steven K GalsonDirector
    Kind
  • Jun 11, 2026Alan G LevinDirector
    Kind
  • Jun 11, 2026Steven FrankDirector
    Kind
  • Jun 11, 2026Machelle SandersDirector
    Kind
  • Jun 11, 2026Vincent MilanoDirector
    Kind
  • Jun 11, 2026Jon P StonehouseDirector
    Kind
  • Jun 11, 2026Amy E McKeeDirector
    Kind
  • Jun 11, 2026Theresa HeggieDirector
    Kind
  • May 29, 2026Jill C. MilneDirector
    Kind
  • May 29, 2026Jon P StonehouseDirector
    Kind
  • May 29, 2026Amy E McKeeDirector
    Kind
  • May 29, 2026Vincent MilanoDirector
    Kind
  • May 29, 2026Steven FrankDirector
    Kind
  • May 18, 2026Amy E McKee
    Kind
  • May 13, 2026Alane P BarnesChief Legal Officer
    Kind10b5-1
  • Mar 20, 2026Theresa Heggie
    Kind
  • Mar 16, 2026Alane P BarnesChief Legal Officer
    Kind10b5-1

From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 2, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.

Insiders and their shares

Every buy and sale by BCRX's officers and directors from 2000 up to November 18, 2025, 26 more calendar years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 3 years.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

4 Holders over 5%Nov 10, 2026 Latest filing
  • BlackRock, Inc.
    Share of class8.40%
  • Deerfield Mgmt, L.P.with 3 more persons
    Share of class6.81%
  • RA Capital Management, L.P.with 3 more persons
    Share of class6.20%
  • Vanguard Capital Management
    Share of class5.16%
Fell to 5% or less (3)

Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.

  • State Street4.80%Nov 10, 202613G
  • The Vanguard Group0.00%Mar 26, 202613G/A
  • Avoro Capital Advisors LLC4.20%May 15, 202513G/A

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • Bridgewater (Dalio)
    In the quarter+74%
  • Renaissance Technologies
    In the quarter-18%
  • Point72 (Cohen)
    In the quarter+63%
  • Millennium Mgmt (Englander)
    In the quarter-65%
  • Citadel Advisors (Griffin)
    In the quarter-57%
  • D.E. Shaw
    In the quarter-16%
  • AQR Capital
    In the quarter-42%

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 10.6% of its shares outstanding were held short, -3.3% since the report before.

Shares held short
26.60M
10.6%
Since the report before27.49M on Sep 30, 2026
-3.3%
5.8
4.58M
More days to cover thanof 4,578 US-listed companies with enough volume
69%
Report date
Oct 15, 2026
  • Oct 31, 2023: Shares held short 30.13M
  • Nov 15, 2023: Shares held short 29.47M
  • Nov 30, 2023: Shares held short 29.38M
  • Dec 15, 2023: Shares held short 29.78M
  • Dec 29, 2023: Shares held short 30.08M
  • Jan 12, 2024: Shares held short 28.05M
  • Jan 31, 2024: Shares held short 29.04M
  • Feb 15, 2024: Shares held short 29.41M
  • Feb 29, 2024: Shares held short 29.10M
  • Mar 15, 2024: Shares held short 30.55M
  • Mar 28, 2024: Shares held short 32.25M
  • Apr 15, 2024: Shares held short 34.39M
  • Apr 30, 2024: Shares held short 33.64M
  • May 15, 2024: Shares held short 34.35M
  • May 31, 2024: Shares held short 36.18M
  • Jun 14, 2024: Shares held short 29.67M
  • Jun 28, 2024: Shares held short 17.88M
  • Jul 15, 2024: Shares held short 21.81M
  • Jul 31, 2024: Shares held short 24.38M
  • Aug 15, 2024: Shares held short 24.81M
  • Aug 30, 2024: Shares held short 24.06M
  • Sep 13, 2024: Shares held short 24.32M
  • Sep 30, 2024: Shares held short 23.23M
  • Oct 15, 2024: Shares held short 22.53M
  • Oct 31, 2024: Shares held short 20.83M
  • Nov 15, 2024: Shares held short 18.49M
  • Nov 29, 2024: Shares held short 19.36M
  • Dec 13, 2024: Shares held short 17.29M
  • Dec 31, 2024: Shares held short 15.72M
  • Jan 15, 2025: Shares held short 17.01M
  • Jan 31, 2025: Shares held short 17.31M
  • Feb 14, 2025: Shares held short 16.68M
  • Feb 28, 2025: Shares held short 16.01M
  • Mar 14, 2025: Shares held short 19.77M
  • Mar 31, 2025: Shares held short 20.73M
  • Apr 15, 2025: Shares held short 20.44M
  • Apr 30, 2025: Shares held short 18.30M
  • May 15, 2025: Shares held short 20.98M
  • May 30, 2025: Shares held short 24.02M
  • Jun 13, 2025: Shares held short 23.08M
  • Jun 30, 2025: Shares held short 27.22M
  • Jul 15, 2025: Shares held short 26.78M
  • Jul 31, 2025: Shares held short 25.88M
  • Aug 15, 2025: Shares held short 27.08M
  • Aug 29, 2025: Shares held short 27.48M
  • Sep 15, 2025: Shares held short 28.32M
  • Sep 30, 2025: Shares held short 27.57M
  • Oct 15, 2025: Shares held short 30.77M
  • Oct 31, 2025: Shares held short 32.47M
  • Nov 14, 2025: Shares held short 36.46M
  • Nov 28, 2025: Shares held short 37.38M
  • Dec 15, 2025: Shares held short 36.01M
  • Dec 31, 2025: Shares held short 39.06M
  • Jan 15, 2026: Shares held short 43.20M
  • Jan 30, 2026: Shares held short 39.45M
  • Feb 13, 2026: Shares held short 40.32M
  • Feb 27, 2026: Shares held short 40.42M
  • Mar 13, 2026: Shares held short 37.48M
  • Mar 31, 2026: Shares held short 35.19M
  • Apr 15, 2026: Shares held short 38.53M
  • Apr 30, 2026: Shares held short 37.42M
  • May 15, 2026: Shares held short 36.11M
  • May 29, 2026: Shares held short 36.65M
  • Jun 15, 2026: Shares held short 40.64M
  • Jun 30, 2026: Shares held short 48.69M
  • Jul 15, 2026: Shares held short 31.21M
  • Jul 31, 2026: Shares held short 32.80M
  • Aug 14, 2026: Shares held short 32.94M
  • Aug 31, 2026: Shares held short 34.05M
  • Sep 15, 2026: Shares held short 34.87M
  • Sep 30, 2026: Shares held short 27.49M
  • Oct 15, 2026: Shares held short 26.60M

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Short sales in daily trading47.9% of the shares in the last 14 sessions' reported trades were short sales.

In the last 14 sessions, 47.9% of the shares in the reported trades were short sales, against 31.9% in the 14 before.

Last 14 sessionsOct 30, 2026 – Nov 18, 2026
47.9%
The 14 beforeOct 12, 2026 – Oct 29, 2026
31.9%
Change
+16.0 pts
Short sales a dayon average, of 1.47M shares
706.1K
More than atof 3,656 US-listed companies, same days
41%
Median of alleight in ten from 34.4% to 63.7%
50.3%
  • Oct 12, 2026: Short sales 41%
  • Oct 13, 2026: Short sales 40.1%
  • Oct 14, 2026: Short sales 23.1%
  • Oct 15, 2026: Short sales 23.5%
  • Oct 16, 2026: Short sales 39.5%
  • Oct 19, 2026: Short sales 11.7%
  • Oct 20, 2026: Short sales 49.3%
  • Oct 21, 2026: Short sales 70.8%
  • Oct 22, 2026: Short sales 30.9%
  • Oct 23, 2026: Short sales 33.3%
  • Oct 26, 2026: Short sales 39.7%
  • Oct 27, 2026: Short sales 19%
  • Oct 28, 2026: Short sales 27.4%
  • Oct 29, 2026: Short sales 37.6%
  • Oct 30, 2026: Short sales 40%
  • Nov 2, 2026: Short sales 39.7%
  • Nov 3, 2026: Short sales 40.8%
  • Nov 4, 2026: Short sales 50.5%
  • Nov 5, 2026: Short sales 57.5%
  • Nov 6, 2026: Short sales 32.5%
  • Nov 9, 2026: Short sales 36%
  • Nov 10, 2026: Short sales 52.4%
  • Nov 11, 2026: Short sales 40.8%
  • Nov 12, 2026: Short sales 49.5%
  • Nov 13, 2026: Short sales 46%
  • Nov 16, 2026: Short sales 62.6%
  • Nov 17, 2026: Short sales 44.1%
  • Nov 18, 2026: Short sales 46.9%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.

What the insiders hold

The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.

3.28M Insiders' shares1.31% Of the company
  • Jon P StonehousePresident & CEO
    Directly1.42M
  • Alane P BarnesChief Legal Officer
    Directly400.7K
  • Charles K GayerChief Commercial Officer
    Directly307.5K
  • Helen M. ThackrayChief R&D Officer
    Directly272.1K
  • Anthony DoyleChief Financial Officer
    Directly266.7K
  • Vincent MilanoDirector
    Directly109.6K
  • Nancy J HutsonDirector
    Directly86.6K
  • Steven K GalsonDirector
    Directly86.2K
  • Theresa HeggieDirector
    Directly80.6K
  • Alan G LevinDirector
    Directly79.6K
  • Amy E McKeeDirector
    Directly47.8K
  • Machelle SandersDirector
    Directly45.9K
  • Steven FrankDirector
    Directly36.7K
  • Jill C. MilneDirector
    Directly33.2K
  • Steve AselageDirector
    Directly–

A lower bound: it counts only the 15 officers and directors with a market trade since Nov 20, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.

The ETFs that hold it

Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

21 ETFs holding it0.89% The largest weight (XBI)
  • XBIState Street(R) SPDR(R) S&P(R) Biotech ETF
    Weight in the fund0.89%
  • LABUDirexion Daily S&P Biotech Bull 3X Shares
    Weight in the fund0.59%
  • IBBiShares Biotechnology ETF
    Weight in the fund0.17%
  • IWOiShares Russell 2000 Growth ETF
    Weight in the fund0.14%
  • FESMFidelity Enhanced Small Cap Core ETF
    Weight in the fund0.12%
  • IWMiShares Russell 2000 ETF
    Weight in the fund0.07%
  • VTWOVanguard Russell 2000 Index Fund
    Weight in the fund0.07%
  • SCHASchwab U.S. Small-Cap ETF
    Weight in the fund0.05%
  • DFASDimensional U.S. Small Cap ETF
    Weight in the fund0.05%
  • VBKVanguard Small-Cap Growth Index Fund
    Weight in the fund0.04%

21 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

318 Managers, Q2 2026$2.6B Value of their positions
  • Q3 2025: Managers 288
  • Q4 2025: Managers 274
  • Q1 2026: Managers 304
  • Q2 2026: Managers 318

Institutional investors by quarter

The fund managers holding BCRX, quarter by quarter, from Q1 2013 to Q2 2025, 50 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 12 quarters.

Q2 2026: 318 managers held 264M shares, worth $2.6B. During the quarter 56 opened a position, 42 closed one, 131 added and 84 trimmed.

The largest holders, Q2 2026

  • BlackRock
    In the quarter+5.5%
  • Ra Capital Management
    In the quarter
  • State Street
    In the quarter+24%
  • Deerfield Management
    In the quarter+0.4%
  • Vanguard Capital Management
    In the quarter+2.1%
  • Vanguard Portfolio Management
    In the quarter-0.9%
  • TCG Crossover Management
    In the quarter
  • Perceptive Advisors
    In the quarter+39%
  • Jupiter Topco
    In the quarter
  • Vestal Point Capital
    In the quarter+18%

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.

The full analysis

What do BioCryst Pharmaceuticals's filings show?

Who buys and sells is one part of BioCryst Pharmaceuticals's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about BCRX's shareholders

Didn't find what you were looking for?

Ask us
Have BCRX's insiders bought or sold?

From Jun 2, 2026 to Sep 2, 2026 BioCryst Pharmaceuticals's insiders reported no purchase or sale of shares on the market.

Which well-known managers hold BCRX?

7 of the managers we track held the shares on Sep 30, 2026. The largest position was Renaissance Technologies's, worth $17M.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.